MSTO1

Across TCGA pan-cancer cohorts, MSTO1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MSTO1 data layer compared with 29 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MSTO1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSTO1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

LUAD, UCEC, and CCRCC are the cancer types where MSTO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.442	1.000	.005	25	view →
UCEC	DFS	Median	III,IV	1.000	0.386	.002	18	view →
CCRCC	OS	Quartile	All	0.876	1.000	.017	14	view →
LSCC	OS	Quartile	II,III,IV	0.661	1.000	.013	9	view →
PDAC	DFS	Median	III,IV	0.310	0.693	.006	9	view →
HNSC	DFS	Median	All	0.855	0.687	.014	7	view →
GBM	OS	Median	All	0.429	0.635	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MSTO1–LUAD (DFS)

Open the LUAD breakdown →